Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Berkshire Hathaway Inc Class BTrade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs ClearPoint Neuro Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $510.05, while ClearPoint Neuro Inc trades at $14.71 (market cap $454.21M). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.

BRK.BCLPT
Sector
FinancialsHealth
52-Week High
$529.65$29.60
52-Week Low
$465.39$8.66
Market Cap
$454.21M
Enterprise Value
$488.79M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.

The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT